UCB’s Head of Digital Business Transformation, Colin Lake speaks to the current landscape in digital business transformation and neurology.

To better understand the experiences of Hispanic people with epilepsy and to improve our collective effort to break down barriers to equitable health outcomes, UCB is working with patients and their families, as well as health equity experts. Learn more.

The U.S. Food and Drug Administration has reviewed new drug stability data and approved a shelf life extension from 12 to 24 months for NAYZILAM® (midazolam) nasal spray, CIV. NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older.¹

During my time in the Navy, I developed a strong sense of purpose, service and mission. After fulfilling my service obligation, I was eager to find another career that continued to allow me to do something larger than myself. I found at UCB, a company that makes medicines to help improve the lives of people living with epilepsy, a different type of service: service to patients.

UCB spoke with caregiver, Debbie, about her experience caring for her daughter living with epilepsy and its personal impact on her, as well as the important role of telehealth in epilepsy care. Her story speaks to the challenges many caregivers face when looking after their loved ones and the importance of prioritizing their own mental health. As one of UCB’s Epilepsy Advocates and as a patient advocate for the Epilepsy Foundation, Debbie supports others living with epilepsy and their families throughout their healthcare journey. In these roles, she helps many find access to the right mental health resources, which she says can be a “game changer” for both epilepsy patients and their loved ones.